Current Breathometer Valuation and Funding History
Breathometer's valuation has been shaped by its early-stage funding rounds and public perception as a health-tech startup. The company, founded by Charles Michael Yim, raised seed funding and later secured Series A capital to develop its smartphone-connected breathalyzer hardware and software platform. Specific post-money valuation figures from private markets have not been publicly disclosed in recent SEC filings or major financial news outlets, but the company's ability to attract venture capital has been documented in industry reports. The company's initial public messaging and product launches generated significant media attention, which contributed to its perceived market value before regulatory hurdles emerged. For a detailed history of its funding and corporate structure, one can refer to the company's public disclosures and tech press coverage Forbes.
The core technology behind Breathometer's value proposition was a portable device that synced with a mobile app to estimate blood alcohol content. The company positioned itself as a consumer wellness tool, leveraging smartphone sensors and algorithms to provide quick readings. This approach attracted early adopters and investors interested in the intersection of mobile health and personal safety. However, the hardware component faced scrutiny regarding accuracy compared to professional-grade ignition interlock devices. The transition from a hardware-centric model to a software-focused or service-based model would directly impact how the company's assets are currently valued by any potential acquirers or partners.
Regulatory Actions and Their Impact on Company Worth
The Federal Trade Commission took enforcement action against Breathometer, which significantly affected the company's market standing and asset valuation. The FTC complaint alleged that the company's breathalyzer app provided inaccurate blood alcohol content estimates, leading to a settlement that required the company to cease deceptive marketing practices. This regulatory outcome reduced the commercial viability of the original product and influenced investor confidence. The settlement details, including any financial penalties or mandated corrective actions, are part of the public record and are accessible through federal agency databases FTC.gov.
Following the FTC action, the company's intellectual property, including its app software and brand, became subjects of interest in discussions about asset liquidation or pivot strategies. The value of Breathometer's technology stack is now largely contingent on the utility of its software algorithms independent of the original hardware claims. Any current valuation would likely be based on the residual value of its codebase, user data, and the Breathometer trademark, rather than the original device sales figures. This shift from a hardware to an intangible-asset valuation model is common in tech startups facing regulatory setbacks.
Current Market Position and Asset Assessment
As of the latest available public information, Breathometer operates with a significantly reduced footprint compared to its peak promotional period. The company's current market position is defined by its intellectual property portfolio and the lessons learned from its regulatory challenges. The value of the Breathometer name is now tied to the cautionary tale of consumer health tech marketing and the importance of clinical validation. Potential buyers or licensees would assess the company's assets based on the remaining software capabilities and the dataset accumulated during its active years. The company's evolution reflects broader trends in the digital health sector, where regulatory compliance is a prerequisite for sustainable valuation SEC EDGAR.
The financial worth of Breathometer today is not measured in active revenue streams from a consumer product but in the strategic value of its technology and brand for potential integration into larger health and wellness platforms. The company's journey from a celebrated Kickstarter project to a subject of FTC oversight provides a concrete case study in startup valuation